![]() | DCGI approves market authorisation for SII's Covid vaccine Covovax as heterologous booster doseCovovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation. |
![]() | Commercial use of SII’s Covovax as heterologous booster jab gets government nodAccording to officials, the subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO), which met on Wednesday, deliberated on the issue. |
![]() | COVID-19: Covovax to get approval as booster in 10-15 days, says SII CEO Adar PoonawallaCovovax works very well against omicron variant,more than Covishield, says Adar Poonawalla. |
![]() | SII seeks nod to export 32.4 lakh doses of its Covid vaccine Covovax to USThe sources said it will be the first instance of any Indian manufacturer's vaccine -- Covid or non-Covid -- to be exported to the US. |
![]() | Government panel recommends emergency approval for SII's Covovax for 7-11 year oldsThe DCGI had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject to certain conditions on March 9. |
![]() | SII's COVID vaccine Covovax now available for 12-17 age group at private centresChildren aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal. |
![]() | Poonawalla warns against return to business-as-usual approachCalling for increased adoption of booster doses, Poonawalla said it is also needed because people need to travel internally and outside, many countries have made booster doses mandatory for travel. |
![]() | Panel seeks more data on Serum Institute's EUA application for Covovax useThe SII had last month submitted an application to the Drugs Controller General of India (DCGI) seeking emergency use authorisation (EUA) for Covovax's use among children in the age group. |
![]() | Govt panel recommends inclusion of Covovax in national Covid vaccination drive for those aged 12 and aboveIndia's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12-17 age group, subject to certain conditions, on March 9. |
![]() | India's drugs regulator gives nod to phase-3 clinical trial of Covid vaccine CovovaxCDSCO had recommended permission for conducting phase-3 clinical trial for Covovax as booster dose in adults who have been fully vaccinated with either Covaxin or Covishield least three months ago. |
![]() | DCGI's EUA nod to SII's Covovax for 12-17 years age groupPoonawalla says younger age groups to follow shortly |
![]() | Covid: Government panel recommends permission for phase-3 trial of Covovax as booster dose in adultsThe Drugs Controller General Of India (DCGI) has already approved Covovax for restricted use in emergency situations in adults on December 28. |
![]() | Covovax EUA recommended for 12-17 groupThe DCGI had approved Covovax for restricted use in emergency situations in adults on December 28 last year. It is yet to be used in India’s vaccination drive. |
![]() | Government panel recommends EUA for Covid vaccine Covovax for 12-17 age groupThe Drugs Controller General of India (DCGI) had approved Covovax for restricted use in emergency situation in adults on December 28. |
Latest
14 charred to death in massive fire at multi-storey building in Jharkhand's Dhanbad
Severed head of suicide bomber recovered; Pakistan blames 'security lapse' for mosque blast
Joshimath: State government offers flexible rehabilitation plans for disaster-affected people
UPI accounted for 52% of total digital transactions in FY22: Economic Survey
Adani Group acquires Haifa port for USD 1.2 bn, Israeli PM lauds deal as 'enormous milestone'